![No Surprises Act Controversy Takes Surprising Twist](https://www.g2intelligence.com/wp-content/uploads/2023/03/April23.NLR_.SurpriseBilling-iStock-1800x1250-1-1080x675.jpg)
No Surprises Act Controversy Takes Surprising Twist
Resolution process put on hold after federal court again strikes down parts of the regulation as being unfairly weighted in favor of insurers.
Resolution process put on hold after federal court again strikes down parts of the regulation as being unfairly weighted in favor of insurers.
Hopes are high that something will finally be done to resolve the LDTs situation this year, however that action may not come from Congress.
The rules unfairly favor insurers in out-of-network payment disputes, court says.
While the federal spending bill passed at the end of 2022 will have a large impact on clinical labs, it doesn’t include LDTs reform.
Legislation offering permanent relief from both PAMA price cuts and reporting didn’t make it into the federal spending bill passed Dec. 23.